Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but the leak sparked heavy selling due to high expectations. Despite the drop, Moderna shares remain up 526% year-to-date. Investors await a full presentation at the European Society for Medical Oncology (ESMO) Congress for clearer insights, while BioNTech and Pfizer saw smaller stock movements amid the news.
Moderna's stock is down 24.94% on Pluang as of Oct 23, 2026 01:11 WIB, closely matching the reported drop. BioNTech shares also fell slightly by 1.37%, while Pfizer edged up 1.34% during the same period. Merck's stock dipped 1.36%, with Pluang showing a typical hold time of 96 days for Merck investors.
Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technolog...
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
